Compare · BDX vs VVOS
BDX vs VVOS
Side-by-side comparison of Becton Dickinson and Company (BDX) and Vivos Therapeutics Inc. (VVOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and VVOS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.08B, about 7887.9x VVOS ($5.5M).
- Over the past year, BDX is down 14.5% and VVOS is down 91.6% - BDX leads by 77.1 points.
- BDX has been more active in the news (4 items in the past 4 weeks vs 3 for VVOS).
- BDX has more recent analyst coverage (25 ratings vs 1 for VVOS).
- Company
- Becton Dickinson and Company
- Vivos Therapeutics Inc.
- Price
- $156.38+2.24%
- $0.40+1.72%
- Market cap
- $43.08B
- $5.5M
- 1M return
- +5.81%
- -10.00%
- 1Y return
- -14.52%
- -91.60%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 1
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Vivos Therapeutics Inc.
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Latest BDX
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Mike Garrison to Retire from BD
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
Latest VVOS
- SEC Form 4 filed by Large owner Skaff Michael C
- SEC Form 3 filed by new insider V-Co Investors 4 Llc
- Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants
- Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
- Vivos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
- Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
- Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026